Kornimate/medical-research-clean huggingface dataset:
long-term outcomes of implants in patients with periodontitis

Conditions: Peri-Implant Health; Periodontitis; Peri-implant Mucositis; Peri-implantitis

Summary: the aim of the study is to examine potential influencing factors on the changes in the periodontal parameters probing pocket depth (ppd), bleeding on probing (bop), and alveolar bone loss (abl) on implants and control teeth (using a split-mouth design) over five (t-5), 7.5 (t-7), and ten years (t-10) of supportive periodontal care (spc). for this purpose, 150 patients with periodontitis and implants are re-examined cross-sectionally (t0), and the changes in the main peri-implant and periodontal target parameters are compared retrospectively at the specified observation time points (t-5, t-7, t-10). potential influencing factors to peri-implant conditions include patient-related factors, therapy-related factors and implant-related factors. in addition, patients will be surveyed using validated questionnaires on oral health-related quality of life (ohip-g14), and a number of common risk factors for periodontits and peri-implant conditions.


Eligibility criteria:
inclusion criteria: patient-related: * at least one dental implant present * age ≥ 18 years at the beginning of the observation period * verbal and written consent * complete periodontal and dental status at one of the defined observation time points with 6 probing sites per tooth/implant and bleeding on probing (bop) recorded during the periodontal maintenance phase locally: * a contralateral control tooth to the implant is present at the first defined observation time point * bop recorded on the implant exclusion criteria: * no written and verbal consent * younger than 18 years
prospective randomized trial of navigated and conventional tka

Conditions: Osteoarthritis of the Knee

Summary: evaluation of the component position and kinematics after navigated and conventional total knee arthroplasty.

1. component position, kinematics after skin closure lateral x-rays were done in different flexion angles in order to evaluate the kinematic behaviour of the tka. a full-length standing and a lateral radiograph as well as ct scans of the hip, knee and ankle joint were performed 5 to 7 days postoperatively before discharge. 2. clinical outcome patient sociodemographic and anamnestic data were collected. the written interview was complemented by the euroqol questionnaire (release eq-5d) and the assessment of the patients' functional status (knee society score) one week before surgery and 18 to 24 month after surgery.

Eligibility criteria:
inclusion criteria: * primary or secondary osteoarthritis of the knee * indication to tka * a mechanical axis between 20° varus and 5° valgus * signed informed consent exclusion criteria: * previous hemi- or total arthroplasty * severe instability that could not be treated with an unconstrained, cruciate-retaining tka

Keywords: total knee arthroplasty navigation
study of enzalutamide (formerly mdv3100) as a neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.


Eligibility criteria:
inclusion criteria: * willing to provide informed consent * 18 years of age or older * histologically confirmed adenocarcinoma of the prostate * must be a candidate for radical prostatectomy and considered surgically resectable exclusion criteria: * stage t4 prostate cancer by clinical or radiologic evaluation * treatment with an investigational agent within 4 weeks prior to randomization * received therapy for other neoplastic disorders within 5 years * hypogonadism or severe androgen deficiency

Keywords: prostate cancer prostatectomy neoadjuvant
anti-pd-1 antibody and p-gemox chemotherapy combined with radiotherapy in high-risk early-stage enktl

Conditions: Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type; Early-stage; High-Risk Cancer

Summary: the current study is a phase ii multi-center single arm trial to evaluate the efficacy and safety of inductive anti-pd-1+p-gemox treatment followed by radiotherapy and concurrent anti-pd-1 antibody in early-stage high-risk extranodal nk/t cell lymphoma, nasal type


Eligibility criteria:
inclusion criteria: * biopsy proved extranodal nk/t cell lymphoma * no previous anti-cancer treatment * measurable lesion on baseline pet/ct and mri * stage i-ii * have at lest one following risk factor: elevated serum ldh level; pti+; stage ii * ecog ps 0-1 * sufficient organ functions exclusion criteria: * other mature t- or nk- lymphoma * hemophagocytic lymphohistiocytosis * primary cns lymphoma or cns-involved lymphoma * history of malignancy except for cutaneous basal-/squamous- cell carcinoma or cervical carcinoma in situ 3 years prior to study treatment

Keywords: nk/t-cell lymphoma, nasal and nasal-type anti-pd-1 antibody radiotherapy chemotherapy pegaspargase
muscle synergies after stroke

Conditions: Stroke

Summary: the aim of this systematic review was to determine the number of muscle synergies and the distribution of muscle weightings in stroke patients during gait.

the aim of this systematic review was to determine the number of muscle synergies and the distribution of muscle weightings in stroke patients during gait. although literature has suggested that merging of synergies occurs after stroke and that a larger number of is associated with increased motor function if compared with healthy adults. iit is still unknown if this hypothesis is also relevant when comparing different functional levels within a stroke population and what functional impact of altered synergies on walking behavior is.

Eligibility criteria:
inclusion criteria stroke: 1. haemorrhagic or ischaemic stroke diagnosis, confirmed on the basis of ct or mri imaging; 2. no known history of previous stroke; 3. stroke onset within five months; 4 patients are between 18 and 85 years of age; exclusion criteria stroke: 1. a score of 20 or higher on the trunk impairment scale which indicates normal truncal function; 2. a score lower than two on the functional ambulation categories (fac) as patients needed to be able to ambulate without physical support to ensure that gait analysis can be executed safely; 3. not able to sit independently for 30 seconds on a stable surface; 4. they suffer from other neurological and orthopaedic disorders that could influence motor performance and balance; 5. not able to understand instructions.

Keywords: muscle synergies gait functional ability
safety and efficacy of linagliptin (bi 1356) as monotherapy or in combination in type 2 dm

Conditions: Diabetes Mellitus, Type 2

Summary: the objective of the current study is to investigate the safety and tolerability of bi 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment. the treatment modalities are determined by the treatment in the blinded trial in which every patient was included previously as bi 1356 in monotherapy (patients in 1218.16 trial), bi 1356 in combination with pioglitazone (patients in 1218.15 trial), bi 1356 added to metformin background (patients in 1218.17 trial) or bi 1356 added to a background therapy of metformin in combination with a sulphonylurea (patients in 1218.18 study)


Eligibility criteria:
inclusion criteria: 1. signed and dated written informed consent in accordance with the gcp and local legislation. 2. patients completing the entire treatment period as a double blind trial whether or not they have been treated with rescue medication. exclusion criteria: 1. patients who meet one or more of the withdrawal criteria of the treatment period of the previous trial. 2. pre-menopausal women (last menstruation =\< 1 year prior to signing informed consent) who: * are nursing or pregnant, * or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. acceptable methods of birth control include transdermal patch, intra uterine devices/systems (iuds/iuss), oral, implantable or injectable contraceptives, true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence \[e.g. calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of birth control) and vasectomised partners. no exception will be made. 3. alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation. 4. drug abuse which, in the opinion of the investigator, would interfere with trial participation. 5. any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication.
a phase ii clinical study to assess the efficacy and safety of ibi310 or placebo combined with sintilimab for advanced cervical cancer subjects who have failed or cannot tolerate first-line or above platinum-based chemotherapy

Conditions: Advanced Cervical Cancer

Summary: this is a randomized, double-blind, controlled, parallel-cohort phase ii clinical study, which is planned to enroll 220 subjects with advanced cervical cancer who have failed or cannot tolerate first-line or above platinum-based chemotherapy


Eligibility criteria:
inclusion criteria: 1. the subject must sign the written informed consent form, and can comply with the visits and related procedures specified in the protocol. 2. aged ≥18 years and ≤75 years. 3. diagnosed with cervical cancer by histology/cytology. 4. patients with relapsed or metastatic cervical cancer who have had progressed or relapsed after receiving at least first-line of platinum-based chemotherapy (if a patient has progressed or relapsed during or within 6 months after receiving platinum-based neoadjuvant or adjuvant chemotherapy, she will be deemed to have received first-line treatment). 5. the subject's previous systemic treatment must have ended ≥4 weeks before the first study administration, and the treatment-related aes have recovered to common terminology criteria for adverse events (ctcae) v5.0 grade ≤1 (except for alopecia and fatigue). exclusion criteria: 1. diagnosis of other malignant tumors within 5 years before the first administration, excluding radically cured skin basal cell carcinoma, skin squamous cell carcinoma, radically resected carcinoma in situ and/or thyroid papillary carcinoma. 2. pleural effusion, ascites, and pericardial effusion with clinical symptoms or requiring drainage (patients with effusion that does not require drainage or patients with no significant increase in the effusion within 3 days after stopping drainage can be selected). 3. patients who are planning to undergo or have previously received organ or bone marrow transplantation. 4. patients with acute or chronic active hepatitis b or c infection, hepatitis b virus (hbv) dna\> 200 iu/ml or 103 copies/ml; hepatitis c virus (hcv) antibody positive and hcv-rna level higher than the lower limit of detection. patients with acute or chronic active hepatitis b or c infection who have received nucleotide antiviral therapy and are below the above standards can be selected. 5. meningeal metastases or symptomatic central nervous system (cns) metastases. patients with asymptomatic brain metastases who do not need treatment with glucocorticoids, anticonvulsants or mannitol after radiotherapy can be enrolled.
outcomes of karydakis, primary closure, and pit picking methods in the treatment of pilonidal sinus: a prospective study in women

Conditions: Pilonidal Sinus

Summary: although there are many methods for the surgical treatment of pilonidal sinus disease, the number of studies specific to women is limited in the literature. in addition to post-treatment recurrence and complication rates in women, aesthetic results are also of great importance. this study will compare the karydakis procedure, a flap method, and the bascom's pit-pick procedure, a minimally invasive procedure, in terms of recurrence, complications and aesthetics, especially in female patients with three or fewer pits.

this study is a single-center, prospective observational trial aimed at comparing the effectiveness of the karydakis flap and bascom's pit-pick methods in treating pilonidal sinus disease in women. female patients aged 18 and over, with three or fewer pits, will be included, and each patient will be followed for 12 months. the bascom pit-pick method will be performed under local anesthesia, while the karydakis method will be performed under spinal or general anesthesia. postoperative recovery time, complications, recurrence rates, and patient satisfaction will be evaluated. ethics committee approval has been obtained (approval no: te 172, date: june 12, 2024).

Eligibility criteria:
inclusion criteria: * female patients 18 years old and older * diagnosed with pilonidal sinus disease, having 3 or fewer pits. * no previous surgical treatment for pilonidal sinus. exclusion criteria: * under 18 years of age * pregnancy * presented with acute abscesses * patients with recurrent disease, stage-r. * \>3 pit * collagen tissue disease * exceed to navicular area * lateral extension in both directions * accidentally discovered (asymptomatic) sinus or with follow-up \<12 months
evaluation of rupture of galenic practices at home in a population aged 65 or older

Conditions: Geriatric Assessment

Summary: elderly people frequently take several medications and are exposed to iatrogenic risks. the oral route is the preferred route of administration. the effectiveness and the safety of the drugs depend in particular on the modes of administration (frequency of the intake, respect of the doses and the galenic ...). however, these modalities are very little known concerning the treatments intake at home in the elderly population. in a health facility welcoming geriatric patients, the rupture of galenic is frequent and favored by swallowing disorders, dependence, the increase in age, the presence of cognitive disorders or psycho-behavioral disorders. the consequences of the rupture of galenic are numerous, concern the patients but also the caregivers who administer the treatments.

primary objective : - estimate the rupture of galenic prevalence of at least one molecule in a population of subjects aged 65 years or over living at home and taking at least one oral drug for 2 weeks or more. secondary objectives: * identify the drug classes most frequently involved in the rupture of galenic in a population of subjects aged 65 years of age or over at home; * identify the actors of the drug administration in a population of subjects aged 65 years of or over at home; * to determine the medical and sociodemographic factors associated with the rupture of galenic in a population of subjects aged 65 years or over at home; * to determine the modalities of rupture of galenic in a population of subjects aged 65 or over at home.

Eligibility criteria:
inclusion criteria: * subjects aged 65 or over; * patient taking at least one oral medication for two weeks or more; * patient affiliated to a social security scheme; * patient who has agreed to reply to the questionnaire or, in case of inability to agree, agreement obtained from the caregiver or guardian/curator. exclusion criteria: * patient unable to answer questionnaires and without a referent caregiver capable of reply ; * patient having changed residence for two weeks or less; * patient residing in a residential care facility for dependent elderly people.

Keywords: rupture of galenic ederly patients geriatry drug class
efficacy of dexamethasone in treatment of meconium aspiration syndrome

Conditions: Efficacy, Self

Summary: objective: to determine efficacy of dexamethasone in treatment of meconium aspiration syndrome. study design: randomized control trial. place and duration: services hospital, neonatal unit, lahore. during time span of 1st january to 30th june 2021. material and methods total 100 neonates were randomly divided in two groups. group a (n=50) was treated with dexamethasone (cases) and group b (n=50) served as control. dexamethasone was given in dose of 0.2mg/kg, 12 hourly for 7 days after confirmation of diagnosis. infants present in clinical trial were evaluated by ventilation duration (invasive and non-invasive), oxygen therapy and hospital stay.

data was analyzed in statistical analysis spss version 23. means and standard deviation were calculated for duration of non-invasive and invasive ventilation, hospital stay and oxygen therapy. independent sample t test was applied and value \< 0.05 was taken as significant. whereas frequency and percentages were taken for gender, gestation, mode of delivery and outcome of mas and chi-square test was applied, and p value \< 0.05 was taken as significant.

Eligibility criteria:
inclusion criteria: 1. term and post-term babies who met the operational definition of mas (inborn) 2. presenting within 24 hours of life exclusion criteria: 1. preterm babies or babies with congenital malformations 2. preterm babies or babies with dysmorphism 3. preterm babies or babies with hypoxic-ischemic encephalopathy
effects of food form and fitness on appetite and digestion.

Conditions: High and Increasing Contribution of Energy From Beverages in the Diet May Enhance Positive Energy Balance and Weight Gain

Summary: energy-yielding fluids induce weaker appetitive and compensatory dietary responses than energy-matched semi-solids or solids. this is problematic because the high and increasing contribution of energy from beverages in the diet may enhance positive energy balance and weight gain. the prevailing view of the overweight/obesity problem is that it stems from a small, sustained positive energy balance. it follows then that only small changes, perhaps manipulations in the rheological characteristics of the diet, will be required to correct the problem. certain populations that are more prone to weight gain may benefit from such manipulations. obese individuals have a higher beverage intake and experience greater weight loss with reductions in beverage intake. further, there is evidence that obese individuals consume more energy after a liquid pre-load than their lean counterparts, yet there is no difference in energy intake after a solid load. in contrast, habitual exercisers have been shown to have an increased accuracy of short-term regulation of food intake at meals following liquid preloads. a better understanding of the mechanisms by which beverages and energy-matched solid food forms elicit differential appetitive and dietary responses in these populations needed. this research will attempt to identify the influence of physical fitness and body fat on the ability to compensate for the energy content of solid and liquid preloads by reduction in energy intake at a subsequent ad libitum meal (i.e., acute compensation) and over the course of the day (i.e., short-term compensation). furthermore, this study will examine the cognitive contribution to differential responses to energy-matched beverage and solid food forms and the effects of mastication on appetite, gi transit, glycemic response, and selected endocrine responses.


Eligibility criteria:
inclusion criteria: * 18-50 years of age bmi of 18-23 kg/m2 (lean) or 30-35 kg/m2 (obese) sedentary physical activity level (\ 70th¬ percentile of estimated vo2max for age and sex) good health and not taking any medications known to influence appetite non-smokers not pregnant or lactating weight stable (≤ 3 kg within last 3 months) dietary restraint score \<11 on the three factor eating questionnaire (included in the on-line screening questionnaire) glucose tolerant or non-diabetic (fasting blood glucose of \<100 mg/dl) self-reported consumer of breakfast and lunch exclusion criteria: * history or presence of significant metabolic diseases that may impact study results (i.e., endocrine, hepatic, renal disease) individuals planning on starting a new diet or exercise regimen during the course of the study use of obesity pharmacotherapeutic agents or over-the counter anti-obesity agents within the last 3 months underlying conditions such as any cardiovascular, pulmonary, or neurological dysfunction that may be aggravated with exercise

Keywords: obese, liquid, solid, fitness, humans, appetite
emergence agitation in adult patients after intracranial surgery

Conditions: Intensive Care, Surgical; Postoperative Care; Neurosurgery

Summary: emergence agitation is a frequent complication that can have serious consequences during recovery from general anesthesia. however, agitation has been poorly investigated in patients after craniotomy. in this prospective multicenter cohort study, adult patients will be enrolled after craniotomy and emergence agitation will be evaluated. the incidence, risk factors and outcome will be investigated.


Eligibility criteria:
inclusion criteria: * both supratentorial and infratentorial intradural cranial operations exclusion criteria: * unarousable state (sas=1) during the first 24 hours after the operation * interval longer than 24 hours between the end of the surgery and neurosurgical icu admission

Keywords: emergence agitation intracranial surgery general anesthesia incidence risk factor
concurrent chemoradiotherapy for cervical cancer in elderly women

Conditions: Cervical Cancer

Summary: the purpose of this study is to evaluate the efficiency and safety of weekly cisplatin /liposome paclitaxel concurrent chemoradiothrapy in the treatment of locally advanced cervical cancer in elderly women.

concurrent radiotherapy is the standard treatment of inoperable cervical cancer .due to the physical conditions, elderly patients usually associated with medical complications, so generally just receive radiotherapy alone. recently, some retrospective studies have shown that the impact of chemotherapy did not cause an increase in the complication rate among elderly patients as compared to younger patients with cervical cancer, and may improve the survival when concurrent with radiotherapy. cisplatin and paclitaxel are two effective drug in treating cervical cancer, but whether they are safe enough for elderly when concurrent with radiotherapy, there are no clearly reports. in this study ,we replace the conventional dose chemotherapy with weekly cisplatin or lipsome paclitaxel , to compare the efficiency and safety of weekly cisplatin / liposome paclitaxel concurrent chemoradiotherapy and radiotherapy alone in the treatment of cervical cancer in elderly patients.

Eligibility criteria:
inclusion criteria: 1. histologically proven squamous carcinoma of cervix 2. figo stageⅱb and ⅲb 3. over 65 years 4. do not receive other treatment 5. performance index ecog grade 0 to 2 6. normal ecg 7. normal hematological parameters 8. normal renal and liver function tests exclusion criteria: 1. concomitant disease which may adversely affect the outcome 2. poor nutritional status 3. medical or psychological condition precluding treatment 4. previous treatment 5. concurrent treatment for any cancer

Keywords: cervical cancer elderly women concurrent chemotherapy